Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute non-neoplastic portal vein thrombosis~* Compensated cirrhosis (Child class A-B)~* The onset of PVT is within 1 week.~Exclusion Criteria:~* Decompensated liver disease~* Bleeding tendency or recent bleeding event as bleeding peptic ulcer or oesophageal varices~* Neoplastic invasion of the portal vein~* Renal impairment with the creatinine clearance ≤ 30 ml/min~* Pregnancy and breastfeeding~* Hypersensitivity to rivaroxaban~* Concomitant treatment with another anticoagulant~* Concomitant use of clopidogrel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: ACTIVE_COMPARATOR): acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban
- control group (Type: PLACEBO_COMPARATOR): acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).